Targeted Antigen Delivery Vaccines
Greater efficacy, more consistent results and patentable developments: transform your vaccine into a sustainable competitive advantage.
The future of immunization depends not only on discovering new antigens, but on learning how to guide the immune system with precision.
At Benten we develop next-generation vaccines —recombinant or native— designed to interact directly with dendritic cells and other APCs, achieving a more specific, efficient and long-lasting immune activation.
Our platform
Our platform allows antigens to be directed to the immune system in a controlled manner, achieving greater efficacy with lower doses and more consistent results.
But its true value goes beyond biology: every development generated with our technology is patentable, creating new opportunities for intellectual property, competitive differentiation and value expansion for our partners and customers.
-
Greater effectiveness with lower doses
By targeting the antigen to key cells of the immune system, protection is maximized using lower doses, reducing costs and facilitating production scaling.
-
Consistent results
Immune targeting introduces control and predictability in the activation of the immune system, achieving more homogeneous and reproducible responses.
-
Patentable Technologies
Targeted vaccines open up intellectual property opportunities beyond the antigen, generating technological differentiation and sustainable value.
In an environment where innovation defines the advantage, our platform transforms science into a strategic growth tool.
It accelerates validations, optimizes development costs, and strengthens the technological leadership of those who adopt it.
Innovating in immunity is building the future of animal health.
If you’re looking for a way to enhance your formulations and create sustainable value through innovation, contact us and let’s explore together how to take your portfolio to the next level.
Contact us
Frequently asked questions
-
Conventional vaccines rely on passive antigen uptake. Targeted vaccines actively guide the antigen to specific immune system cells, primarily dendritic cells and other antigen-presenting cells (APCs), introducing greater control over how and where the immune response is initiated.
-
It allows for greater efficacy with lower doses, more consistent responses between individuals, a better safety profile, and a clear technological differentiation compared to traditional formulations.
-
Yes, by optimizing antigen presentation and T-cell activation, immune targeting can promote broader and more functional responses, including cellular immunity and cross-recognition of related variants. This is especially relevant when there is high antigenic variability, multiple strains or serotypes are circulating, or protection beyond strict antigenic matching is desired. If limited coverage is a problem with your vaccine, this approach warrants evaluation.
-
Yes, and in many cases it is especially valuable in animal health. Targeted application helps reduce variability in the field, improve coverage, and optimize costs—critical aspects in real-world production systems.
-
Not always. In many projects it is possible to enhance existing antigens, improving their performance through an appropriate targeting strategy, without redesigning the entire vaccine.
-
Yes, by directing the antigen directly to antigen-presenting cells, neutralization by maternal antibodies is reduced and the effective vaccination window in young animals is extended.
-
No, when designed from the start, it can simplify formulation, reduce antigen consumption and improve reproducibility, facilitating transfer to production and industrial scaling.
-
A brief conversation. With some key data, we can assess whether immunological targeting is suitable for your project and what impact it could have on efficacy, coverage, and technological value. Contact us and let’s talk for 10 minutes about your vaccine development.
Still have questions?
If you need more information, contact us via email or schedule a call with us.